Home Health Costs Topics

Health Costs

The MIDTERMS

Democrats Hold a Nearly 2-to-1 Advantage Over Republicans on Handling the Cost of Health Care

Poll: Cost of Health Care and Gas Top Voters’ Midterm Concerns; Democrats Hold Significant Advantage on Health Care Costs and Cost of Living 

Prior to the 2026 midterm elections, health care costs remain tied with gas as voters’ top midterm concerns and the Democrats hold a clear edge over the Republicans Party on who voters trust to handle many top electoral issues, including the cost of health care and the cost of living. Two-thirds of U.S. adults now favor Medicare-for-all, a new high in KFF Polling, but support shifts when competing claims from critics and proponents are heard.

New and noteworthy

Health System Tracker

Is This A Healthcare Economy?

Health care employment has grown faster than other sectors of the economy, with jobs in physician offices, hospitals, outpatient care centers, home health, and other settings increasing over the past year even as the rest of the job market plateaued. 

U.S. Health Spending Is Expected to Reach $9 Trillion by 2034

How Much is Health Spending Expected to Grow?

This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.

How TrumpRx Brand-Name Drug Prices Compare

TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs.

Latest News

More KFF Health News

Stay informed.

Get KFF's latest on Health Costs

Stay informed.

Get KFF's latest on Health Costs

View the Latest: Health Costs

Filter

List Grid

331-340 of 1,629 results

  • Changes in Health Insurance Coverage, 2007-2008: Early Impact of the Recession

    Issue Brief

    This issue brief examines trends in health insurance coverage from 2007 to 2008, a period marked by the start of a deep recession. It finds that the share of the nonelderly population covered by employer-provided insurance declined, the share covered by public programs increased and the number of uninsured people continued to rise. Notably, the economic downturn affected health insurance coverage differently for adults compared to children. The increase of 1.5 million in the number…

  • KFF Health Tracking Poll – April 2019: Surprise Medical Bills and Public’s View of the Supreme Court and Continuing Protections for People With Pre-Existing Conditions

    Feature

    The April 2019 KFF Health Tracking Poll examines the public’s position on the future of ACA and its protections for people with pre-existing medical conditions, in light of the ongoing legal battle which may end up in the Supreme Court. With lawmakers proposing legislation to address surprise medical bills, this month’s survey also measures the public’s support for federal government action to protect patients from having to pay the cost incurred from an inadvertent out-of-network…

  • Snapshots: Distribution of Out-of-Pocket Spending for Health Care Services

    Issue Brief

    How much people should pay out-of-pocket for health care is a much-debated issue in health policy. New health insurance products with higher out-of-pocket shares are becoming more evident in the private market, and some states are considering ways to increase enrollee financial responsibility in state Medicaid programs.  This paper presents information about current out-of-pocket spending by individuals with the purpose of providing context for future health policy discussions. Current proposals suggest that increasing the amount that…

  • COVID-19 preventable mortality

    Issue Brief

    This updated analysis estimates that nationally at least 234,000 deaths from COVID-19 between June 2021 and March 2022 could have been prevented with a primary series of vaccinations. These vaccine-preventable deaths represent 60% of all adult COVID-19 deaths since June 2021, when vaccines first became widely available.

  • Analysis Estimates Up To 2 Million Uninsured People Could Require COVID-19 Hospitalization

    News Release

    Patients Could Still Be on the Hook for Outpatient Costs, Costs If They Test Negative, and Cost Sharing A new KFF analysis estimates that between 670,000 and 2 million uninsured people around the country eventually could be hospitalized with COVID-19, the respiratory disease caused by the novel coronavirus. Reimbursing hospitals for those treatments could cost between $13.9 billion and $41.8 billion. Trump administration has indicated that it plans to reimburse hospitals for the care of…

  • What Do State Plans Reveal About Their Readiness to Distribute COVID-19 Vaccines? 

    News Release

    With hopes that a COVID-19 vaccine or vaccines will be proven safe and effective soon, state and local public health authorities will play a critical role in ensuring the efficient distribution and administration of the vaccine. To assess the readiness of these local governments to take on these responsibilities, KFF reviewed the preliminary vaccine distribution plans submitted to the U.S. Centers for Disease Control and Prevention last month by the states and the District of…

  • March 30 Web Event: Unsung Heroes: The Crucial Role – and Tenuous Circumstances – of Home Care Workers During the Pandemic

    Event Date:
    Event

    Even as the pandemic took a devastating toll on health care workers and older adults in the United States, many home care workers continued to report to work and provide vital care to vulnerable people despite the health risks to themselves and their own families. KFF’s Kaiser Health News and The John A. Hartford Foundation held an interactive web event on March 30 to examine the crucial roles home care workers have played for families during…

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.